Vanguard (TWST) amendment shows 0 shares after Jan 12, 2026 realignment
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting 03/13/2026 activity for Twist Bioscience Corp common stock. The filing states that, after an internal realignment effective 01/12/2026, certain Vanguard subsidiaries will report ownership separately under SEC Release No. 34-39538. The filing shows amount beneficially owned: 0 and percent of class: 0%. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports zero beneficial ownership in TWST after internal disaggregation.
The amendment documents an internal realignment dated 01/12/2026 and states subsidiaries will report separately in reliance on SEC Release No. 34-39538. The filing explicitly lists 0 shares beneficially owned and 0% of the class.
This indicates the reporting aggregation changed; subsequent Schedule 13G/A filings by Vanguard entities may show holdings. Follow future filings for any reappearance of Vanguard-affiliated holdings.
Amendment clarifies reliance on SEC Release No. 34-39538 for disaggregated reporting.
The document cites Release No. 34-39538 and explains that certain subsidiaries or business divisions will report separately. It affirms Vanguard no longer is deemed to beneficially own securities held by those subsidiaries after the realignment.
Signature block shows Ashley Grim signed on 03/27/2026. Future filings by the named subsidiaries should be checked for any reported positions.
FAQ
What does Vanguard's Amendment No. 5 say about its holdings in TWST?
Why is Vanguard reporting separate holdings after the January 12, 2026 realignment?
Who signed the Schedule 13G/A amendment for Vanguard regarding TWST?
Does the filing indicate Vanguard still controls dividends or sale proceeds for TWST shares?
Will Vanguard or its subsidiaries file further reports for TWST?